Abstracts tagged "malignancy and psoriatic arthritis"

Abstract Number: 1595 • 2018 ACR/ARHP Annual Meeting
Malignancy in Psoriatic Disease
Anastasiya Muntyanu¹, Ker-Ai Lee², Justine Y. Ye³, Ari Polachek³, Vinod Chandran⁴, Richard J. Cook² and Dafna D Gladman¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Medicine, Krembil Research Institute, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: There are conflicting data between studies of psoriasis and psoriatic arthritis (PsA), and there have been recent concerns about the potential of anti-TNF agents…
Abstract Number: 1684 • 2015 ACR/ARHP Annual Meeting
Malignancies in Patients with Incident Psoriatic Arthritis 1970-2008 in Relation to a Comparator Cohort: A Population-Based Case-Control Study
Katelynn Wilton^1,2, Brittny T. Major³, Cynthia Crowson³ and Eric L. Matteson⁴, ¹Medical Scientist Training Program, Mayo Clinic, Rochester, MN, ²Medical Scientist Training Program, Mayo Clinic Rochester, Rochester, MN, ³Biostatistics, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: In psoriatic arthritis (PsA), misdirected inflammation and therapeutic use of immunosuppressants causes global immune compromise. Similar immunocompromised states, as in rheumatoid arthritis and psoriasis…
Abstract Number: 1849 • 2014 ACR/ARHP Annual Meeting
Risk of Malignancy Among Medicare Psoriasis/Psoriasis Arthritis Patients
Huifeng Yun¹, Kevin L. Winthrop², Lang Chen³, Wilson Smith⁴, Benjamin Chan⁵, Fenglong Xie⁶, Allison Taylor⁴ and Jeffrey R. Curtis⁷, ¹Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ²Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Oregon Health and Science University, Portland, OR, ⁶Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose The introduction of biologics has greatly changed the treatment of psoriatic arthritis (PsA) and psoriasis (PsO). However, there are concerns regarding the risk of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].